Patient Recruitment Strategies for Rare Disease Clinical Trials

Rare disease clinical trials face a recruitment problem that is fundamentally different from trials involving common conditions. The patients researchers need may be scattered across countries, treated by a small number of specialists, or still searching for a definitive diagnosis after years of inconclusive testing. This diagnostic odyssey can delay identification of eligible participants and make conventional recruitment campaigns difficult to scale.

Patients and caregivers may also be cautious about sharing sensitive health information, particularly within small disease communities where privacy concerns are significant. Unlike high-prevalence conditions, where broad advertising can generate large pools of potential participants, rare disease recruitment depends on precision, trust and clinical relevance.

Effective patient recruitment strategies for rare disease clinical trials therefore need to move beyond transactional site-based recruitment. Genetic and biomarker screening, decentralized trial elements, specialist networks and meaningful partnerships with patient advocacy groups can create a more connected pathway from diagnosis to enrollment.

Partnering With Patient Advocacy Groups and Registries

For many rare diseases, the patient community is one of the most valuable sources of recruitment intelligence. Patient advocacy groups (PAGs) often understand the lived experience of a disease, the specialist networks serving affected patients and the practical barriers that can prevent participation. The FDA has specifically recognized patient organizations as important contributors to rare disease research, including natural history studies, patient input and clinical development.

Trust is particularly important. Patients may be more receptive to information introduced through a disease-specific organization than to an unfamiliar sponsor advertisement. That does not mean PAGs should function as informal recruitment agencies; rather, they can help sponsors communicate transparently and design participation pathways that reflect patient needs.

Natural history studies and disease registries can strengthen this relationship further. A well-designed registry can characterize disease progression, clinical features and relevant patient populations while creating an organized source of information for future research. FDA guidance notes that advocacy and support groups can help identify patients, support recruitment and contribute perspectives on reducing the burden of research participation.

The strongest partnerships begin before the protocol is finalized. Patient advocates can review visit schedules, eligibility criteria, travel requirements and proposed assessments. Their feedback may reveal that an apparently reasonable procedure is impractical for children, patients with severe disability or families already managing intensive care routines.

The result is not simply a larger recruitment pool. It is a trial designed around a better understanding of the population it intends to serve.

Leveraging Biomarker and Genetic Screening Initiatives

Rare disease recruitment increasingly involves identifying patients rather than simply advertising to them. For conditions with a known genetic basis, genomic testing can help move patients from an uncertain clinical presentation toward a potentially trial-relevant diagnosis.

Sponsors and research networks may support testing pathways for patients whose symptoms suggest an inherited disorder but who lack molecular confirmation. Next-generation sequencing panels, exome or genome sequencing and targeted variant analysis can potentially identify disease-associated variants that would otherwise remain undetected. The precise testing strategy depends on the disease, phenotype, laboratory capabilities and clinical context.

This approach can also help address the diagnostic odyssey. NIH research programs have explored combinations of machine learning, genetic analysis and clinical assessment specifically to shorten the time required to diagnose rare diseases.

Partnerships with diagnostic laboratories can create another recruitment pathway. Where appropriate and permitted, laboratory networks may identify clinically relevant biomarkers or genetic findings and establish processes for communicating research opportunities to eligible patients. Any such model must address consent, privacy, data governance and applicable research requirements rather than treating laboratory information as an unrestricted recruitment database.

Artificial intelligence can add another layer. Machine-learning systems can analyze patterns across electronic health records, clinical notes, laboratory results and diagnostic coding to identify patients whose combinations of symptoms or diagnoses warrant further investigation. ICD-10 codes alone are rarely sufficient to establish eligibility, but they can form part of a broader screening algorithm.

The operational objective is straightforward: reduce the distance between the patient who has an unresolved clinical picture and the specialist or study team capable of determining whether a clinical trial is appropriate.

Implementing Decentralized and Borderless Trial Models

Travel can become one of the largest barriers to rare disease clinical trial enrollment. Requiring participants to visit a specialized Center of Excellence every few weeks may be particularly difficult when patients have limited mobility, complex medical needs or caregivers who cannot repeatedly take time away from work and family responsibilities.

Decentralized clinical trial elements can move selected activities closer to the participant. Depending on the investigational product and protocol, this may include telehealth visits, home nursing, local healthcare providers, remote monitoring, digital health technologies or direct-to-patient logistics. The FDA’s 2024 final guidance describes decentralized elements as trial activities conducted at locations other than traditional trial sites, including participants’ homes and local healthcare settings.

The European regulatory network has similarly highlighted home visits, remote monitoring, local care and electronic consent as potential components of decentralized research.

Decentralization does not eliminate the need for specialized centers. Some assessments, infusions, biopsies or safety procedures may still require expert facilities. In those situations, sponsors can reduce friction through coordinated travel, accommodation, caregiver support and centralized scheduling.

For ultra-rare conditions, international recruitment may also be unavoidable. Sponsors may need to coordinate travel documentation, medical visas where applicable, insurance arrangements and cross-border logistics so eligible patients can reach designated sites. These arrangements should be planned during feasibility rather than introduced only after recruitment problems emerge.

Selecting the Right Sites and Key Opinion Leaders

Site selection for rare disease studies should not rely exclusively on historical enrollment volume or performance in unrelated therapeutic areas. A site that recruits efficiently for a common cardiovascular or metabolic study may have little access to patients with an ultra-rare genetic disorder.

The more useful question is: Where are the patients already being diagnosed and treated?

Specialist neurologists, metabolic disease experts, geneticists, pediatric subspecialists and other disease-specific Key Opinion Leaders (KOLs) may have relationships with a substantial portion of the regional patient population. Their referral networks can be more valuable than a large database of generic clinical trial participants.

A hub-and-spoke model can extend that reach. The academic Center of Excellence serves as the central hub for complex assessments, investigator oversight and specialized procedures. Community hospitals, specialist practices and regional clinics act as spokes, helping identify and support eligible patients closer to home.

This model can also improve operational resilience. A patient may complete routine assessments locally while traveling to the hub only when specialist evaluation or an investigational procedure is necessary.

Site feasibility should therefore examine more than investigator experience. Sponsors should assess the site’s disease-specific patient volume, referral relationships, diagnostic capabilities, genetic testing access, caregiver support and ability to coordinate decentralized activities. A smaller specialist site with genuine access to the target population may be more relevant to recruitment than a high-volume site without that disease expertise.

Practical Checklist for Rare Disease Trial Sponsors

Before activating sites, clinical operations teams should test whether the recruitment strategy works from the patient’s perspective.

Advocacy alignment: Have relevant local and international patient advocacy groups reviewed the protocol for visit burden, eligibility requirements, procedures, caregiver responsibilities and communication materials?

Travel and concierge services: If participants must travel, is there a clearly funded process for transportation, accommodation, meals and caregiver expenses? For international participants, are visa and medical-travel requirements understood in advance?

Screening infrastructure: Can potentially eligible patients access appropriate genetic or biomarker testing without unnecessary delays? Are laboratories and specialist sites prepared to confirm results within the recruitment window?

Site connectivity: Do investigators have access to referral networks beyond their own institution? Can satellite clinics support screening or follow-up where appropriate?

Decentralized elements: Can selected assessments be performed remotely or locally without compromising participant safety, data integrity or protocol requirements? FDA guidance emphasizes that decentralized elements require appropriate planning around activities such as remote visits, data collection, investigational products and safety monitoring.

Regulatory readiness: Have the proposed remote and local activities been reviewed against applicable regulatory, ethical and institutional requirements in each participating jurisdiction?

A recruitment plan that answers these questions early is less likely to discover fundamental access problems after site activation.

Framework for Evaluating Rare Disease Recruitment Readiness: An Example Matrix

Sponsors can turn recruitment planning into a structured feasibility exercise by assigning weighted scores to the factors most likely to influence participant access.

Integration with patient registries and advocacy groups — 30%: Determine whether the sponsor has genuine access to established disease communities and relevant registry infrastructure.

Diagnostic feasibility — 20%: Assess whether prospective participants can obtain the molecular, biomarker or clinical confirmation required for screening without creating excessive delays.

Site and KOL network — 20%: Evaluate whether investigators actually manage the target disease and have referral relationships capable of reaching patients beyond their immediate institution.

Decentralization and burden reduction — 15%: Examine how much travel, time and procedural burden the protocol places on participants and caregivers.

Travel and logistics — 15%: Confirm that the budget supports the practical costs of participation.

The matrix should be adapted to the disease and protocol rather than treated as a universal formula. However, weak performance in patient-community integration and burden reduction should trigger a feasibility review even when the underlying therapy is scientifically compelling.

Common Pitfalls and Strategic Red Flags

Several recruitment tactics can appear attractive during planning but create problems once enrollment begins.

• Mass-market advertising for ultra-rare populations: Broad digital campaigns can generate impressions without reaching clinically appropriate patients. Disease-specific communities and specialist referral networks are often more targeted sources.
• Overly burdensome protocols: Frequent hospital visits, invasive procedures or complex assessments can discourage participation, particularly among pediatric patients or people with advanced disease.
• Ignoring caregiver costs: In many rare diseases, a caregiver is essential to participation. Unreimbursed travel, accommodation, meals or lost work can become a practical exclusion factor even when the patient meets every medical criterion.
• Late advocacy engagement: Approaching PAGs only after the protocol is finalized and enrollment is behind schedule limits their ability to influence study design.
• Treating diagnosis as a separate problem: If molecular confirmation is difficult to obtain, recruitment may stall before patients ever reach formal screening.
• Choosing sites by generic performance metrics: Historical enrollment numbers have limited value when the investigator lacks access to the specific rare disease population.

These warning signs point to a broader principle: recruitment problems often originate in protocol design and operational planning rather than in the recruitment campaign itself.

Final Thoughts — Empathy as an Operational Strategy

Rare disease recruitment is ultimately an exercise in reducing friction for people who may already have spent years navigating complex healthcare systems. The most effective patient recruitment strategies for rare disease clinical trials connect patients with trusted communities, appropriate diagnostic pathways, specialist investigators and practical participation support.

Patient advocacy groups, registries, genetic screening, decentralized trial elements and coordinated site networks can work together to make participation more accessible. None is a universal solution, and every approach must remain consistent with patient privacy, informed consent, safety and regulatory requirements.

Sponsors that treat patients and caregivers as active research partners—not simply sources of study data—can build recruitment programs that are more responsive to real-world barriers. That patient-centered approach can support both enrollment and retention while producing a clinical trial experience better aligned with the population the therapy is intended to serve.